GLP-1 weight-loss pills appear to be just as effective as injections, with clinical trials showing similar average weight ...

As blockbuster GLP-1 injectables like Mounjaro, Wegovy and Ozempic gain traction in India, doctors stress that careful ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. The U.S. Food and Drug Administration (FDA) recently ...

GLP-1s are driving traditional drug spending in the U.S. to unprecedented levels, which now outpaces specialty drug spending for the first time, according to a March 25 report from Evernorth. The ...

On the heels of STRIDE, one of the first trials to show glucagon-like peptide-1 (GLP-1) receptor agonists can help patients with PAD, a retrospective study of more than 100,000 patients provides more ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. 1,2 For ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...

SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...